--- title: "Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields" type: "News" locale: "en" url: "https://longbridge.com/en/news/295539739.md" description: "Benzinga highlights analyst ratings for three high-dividend healthcare stocks: Medtronic (MDT), GSK, and Bristol-Myers Squibb (BMY). Accurate analysts have issued mixed views, including upgrades to Buy for MDT and BMY, while GSK saw a downgrade. Recent developments include MDT's expanded CE Mark indications, GSK's strong Q2 results, and BMY's $2.3 billion investment in a Houston manufacturing campus." datetime: "2026-08-11T12:39:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295539739.md) - [en](https://longbridge.com/en/news/295539739.md) - [zh-HK](https://longbridge.com/zh-HK/news/295539739.md) generator: "portal-rs" --- # Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy. Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. ### **Medtronic PLC (NYSE:MDT)** - **Dividend Yield:** 3.22% - **UBS** analyst Priya Sachdeva upgraded the stock from Neutral to Buy and raised the price target from $85 to $100 on July 28, 2026. This analyst has an accuracy rate of 61%. - **TD Cowen** analyst Joshua Jennings maintained a Buy rating and cut the price target from $119 to $100 on July 10, 2026. This analyst has an accuracy rate of 56%. - **Recent News:** On Aug. 6, Medtronic announced expanded CE Mark indication for Affera Mapping and Ablation System and Sphere-9 Catheter for treatment of ventricular arrhythmias. - Benzinga Pro’s real-time newsfeed alerted to latest MDT news. ### **GSK plc (NYSE:GSK)** - **Dividend Yield:** 3.48% - **Barclays** analyst James Gordon downgraded the stock from Equal-Weight to Underweight on Jan. 6, 2026. This analyst has an accuracy rate of 67%. - **Jefferies** analyst Michael Leuchten upgraded the stock from Hold to Buy on Oct. 27, 2025. This analyst has an accuracy rate of 59%. - **Recent News:** On July 28, GSK reported better-than-expected second-quarter financial results and issued FY31 sales guidance above estimates. - Benzinga Pro’s real-time newsfeed alerted to latest GSK news ### **Bristol-Myers Squibb Co (NYSE:BMY)** - **Dividend Yield:** 3.89% - **Argus Research** analyst Jasper Hellweg upgraded the stock from Hold to Buy with a price target of $75 on Aug. 5, 2026. This analyst has an accuracy rate of 55%. - **Citigroup** analyst Geoff Meacham maintained a Neutral rating and raised the price target from $66 to $70 on Aug. 3, 2026. This analyst has an accuracy rate of 74% - **Recent News:** On Aug. 10, Bristol Myers Squibb announced plans to invest $2.3 billion in Houston manufacturing campus, creating nearly 500 jobs. - Benzinga Pro’s real-time newsfeed alerted to latest BMY news *Photo via Shutterstock* ### Related Stocks - [MDT.US](https://longbridge.com/en/quote/MDT.US.md) - [BMY.US](https://longbridge.com/en/quote/BMY.US.md) - [GSK.US](https://longbridge.com/en/quote/GSK.US.md) - [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [TD.US](https://longbridge.com/en/quote/TD.US.md) - [BCS.US](https://longbridge.com/en/quote/BCS.US.md) - [JEF.US](https://longbridge.com/en/quote/JEF.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md) - [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md) - [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md) - [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) ## Related News & Research - [232,697 Shares in Bristol Myers Squibb Company $BMY Acquired by Beacon Pointe Advisors LLC](https://longbridge.com/en/news/297394340.md) - [Medtronic Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call](https://longbridge.com/en/news/297311060.md) - [Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares](https://longbridge.com/en/news/296941366.md) - [GSK: FDA Accepts SBLA For Jemperli With Priority Review](https://longbridge.com/en/news/296744801.md) - [Key facts: Jemperli BLA Accepted for GSK; Hibsago Approved in Japan](https://longbridge.com/en/news/296749168.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**